Navigation Links
Symmetry Medical Extends 10-K Filing Beyond April 14, 2008 Target

WARSAW, Ind., April 14 /PRNewswire-FirstCall/ -- Symmetry Medical Inc. (NYSE: SMA), a leading independent provider of products to the global orthopedic device industry and other medical markets, today announced that the filing of its 2007 Annual Report on Form 10-K with the Securities and Exchange Commission will be delayed beyond its previously announced April 14, 2008 target. The filing is now in the final stages and the work is substantially completed. The Company said the focus is now on formatting the data, completing the financial statements and preparing the filings.

Symmetry has informed its lead bank of the filing timing change and expects to continue discussions with the bank over the next few days as the filings are finalized.

Brian Moore, President and Chief Executive Officer, said, "We are working diligently with our outside auditing team to file our 2007 Form 10-K as soon as possible. This has been an extremely challenging and time consuming process for management and the audit committee. We believe we are coming to the finalization of the process. Meanwhile, the Company's business continues strong in an orthopedic environment that we believe will result in a robust year for Symmetry's business."

About Symmetry Medical Inc.

Symmetry Medical Inc. is a leading independent provider of implants and related instruments and cases to the orthopedic device industry. The Company also designs, develops and produces these products for companies in other segments of the medical device market, including arthroscopy, dental, laparoscopy, osteobiologic and endoscopy sectors and provides limited specialized products and services to non-healthcare markets, such as the aerospace market.

Forward-Looking Statements

Statements in the press release regarding Symmetry Medical Inc.'s business and regarding our Audit Committee's investigation and related restatement, which are not historical facts, may be "forward-looking statements" that involve risks and uncertainties, within the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are predictive in nature and are frequently identified by the use of terms such as "may," "might," "will," "should," "expect," "believe," "anticipate," "plan," "estimate," "intend," and similar words indicating possible future expectations, events or actions. Such predictive statements are not guarantees of future performance, and actual outcomes and results could differ materially from our current expectations. Certain factors that could cause actual results to differ include: the loss of one or more customers; the development of new products or product innovations by our competitors; product liability; changes in management; changes in conditions effecting the economy, orthopedic device manufacturers or the medical device industry generally; and changes in government regulation of medical devices and third-party reimbursement practices. We refer you to the "Risk Factors" and "Forward Looking Statements" sections in the Company's most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission as well as the Company's other filings with the SEC, which are available on the SEC's Web site at

Investors/Media: Contact:

The Ruth Group Symmetry Medical Inc.

Nick Laudico/Jason Rando Fred L. Hite

(646) 536-7030/7025 Senior Vice President Chief Financial Officer (574) 371-2218

SOURCE Symmetry Medical Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Symmetry Medical Discloses Accounting Issues at Sheffield, UK Operating Unit and Possible Restatement
2. Symmetry Medical to Provide Third Quarter 2007 General Business Update on November 7, 2007
3. Symmetry Medical Reports Preliminary Third Quarter Revenue
4. Symmetry Medical Expands Board of Directors
5. Symmetry Medical Reports Preliminary Fourth Quarter Revenue
6. Symmetry Medical to Present at Canaccord Adams Small-Cap Orthopedics Conference
7. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
8. VisEn Medical Files Action to Invalidate New Caliper Life Sciences Patent
9. China Medical Technologies to Participate in the Morgan Stanleys 2007 China Medical Corporate Day
10. Pathway Medical Technologies Adds Joe Rafferty as VP, Sales, and Moves To Larger Facility to Accommodate Rapid Growth
11. BioMS Medical announces its intention to renew a normal course issuer bid
Post Your Comments:
(Date:10/9/2017)... ... 2017 , ... At its national board meeting in North Carolina, ARCS® ... Departments of Physics and Astronomy, has been selected for membership in ARCS Alumni ... the 2015 Breakthrough Prize in Fundamental physics for the discovery of the accelerating expansion ...
(Date:10/9/2017)... San Antonio, Texas (PRWEB) , ... ... ... a new study published on October 5, 2017, in the medical journal, ... demonstrated equivalence with the gold standard, video EEG, in detecting generalized tonic-clonic ...
(Date:10/7/2017)... ... October 06, 2017 , ... Phase ... metagenome deconvolution product, featuring the first commercially available Hi-C kit. Researchers can ... Hi-C metagenome deconvolution using their own facilities, supplementing the company’s full-service ProxiMeta ...
(Date:10/6/2017)... ... October 06, 2017 , ... The ... and technology sector at their fourth annual Conference where founders, investors, innovative practitioners ... and the ELEVATE pitch competition showcasing early stage digital health and med tech ...
Breaking Biology Technology:
(Date:4/13/2017)... 13, 2017 According to a new market research ... Analytics, Identity Administration, and Authorization), Service, Authentication Type, Deployment Mode, Vertical, and ... is expected to grow from USD 14.30 Billion in 2017 to USD ... 17.3%. ... MarketsandMarkets Logo ...
(Date:4/11/2017)... NXT-ID, Inc. (NASDAQ:   NXTD ) ("NXT-ID" or ... independent Directors Mr. Robin D. Richards and Mr. ... the company,s corporate governance and expertise. ... Gino Pereira , Chief Executive Officer said," ... and benefiting from their considerable expertise as we move forward ...
(Date:4/5/2017)... KEY FINDINGS The global market ... CAGR of 25.76% during the forecast period of 2017-2025. ... for the growth of the stem cell market. ... MARKET INSIGHTS The global stem cell market is segmented ... The stem cell market of the product is segmented ...
Breaking Biology News(10 mins):